Nijmegen, Netherlands – 17.12.25 – Symeres, a leading contract research, development, and manufacturing organisation (CRDMO), has received its first approval from the Science Based Targets initiative (SBTi) for its greenhouse gas (GHG) emissions reduction targets. This marks a major milestone in Symeres’ environmental strategy and affirms its commitment to building a more sustainable, low-carbon future.
This validation confirms the company’s GHG reduction goals align with the latest climate science and meet the requirements to limit global temperature rise to 1.5 degrees Celsius under the Paris Agreement. The SBTi is one of the most important climate action benchmarks for Symeres’ global pharmaceutical clients.
“This isn’t the beginning of our sustainability efforts, but it’s a major milestone in making them visible,” said Jorg Benningshof, ESG lead at Symeres and Head of Scientific Operations.
“SBTi’s approval for our ambitious GHG reduction targets demonstrates our commitment and helps our customers, who are actively building their own sustainability initiatives, to achieve their GHG reduction goals.”
As part of its climate strategy, Symeres has implemented plans to transition to 100% renewable electricity by 2030. In parallel, the company has committed to replacing natural gas-powered systems with electricity-based alternatives when retrofitting facilities. These steps are part of a structured roadmap to reduce the company’s carbon footprint and modernize its infrastructure in alignment with climate goals.
Symeres’ emissions fall under Scope 3, Category 1 for clients, classified as purchased goods and services. By committing publicly to SBTi-validated targets, the company supports its clients in meeting their own environmental goals, particularly large pharmaceutical organisations pursuing net-zero strategies.
“Symeres’ emissions fall under Scope 3, Category 1 as purchased goods and services for clients. By publicly committing to SBTi-validated targets, Symeres helps its clients, especially large pharmaceutical organizations striving for net-zero achieve their environmental objectives.
“Committing to science-based targets strengthens our position as a responsible partner and demonstrates our support for their sustainability initiatives.” added Benningshof.
Symeres’ validation comes at a time when stakeholders, including clients, regulators, investors, and employees expect concrete action on ESG issues. The company discloses its sustainability progress through several recognised frameworks, including the Carbon Disclosure Project (CDP), and Ecovadis.
“Our clients are committed to meet ambitious climate targets. Since most of their emissions come from indirect sources, they rely on partners like us to reduce their environmental footprint,” said Mark Verhaar, Project Manager at Symeres. “SBTi validation shows we’re aligned with their goals and taking meaningful action.”
Latest news
Symeres Appoints Jurgen Berendsen as Chief Financial Officer
Symeres appoints Gabriella Gentile as Chief Operating Officer to drive transatlantic growth
Symeres announces acquisition of DGr Pharma
Symeres and Yoneda Labs use AI to optimize cross-coupling reactions
New production lines D1 and D2 at our Prague site
New NMR technology – meet “Maggie”
Symeres announces leadership evolution
Official opening of new Oncolines home, the Marie Curie Building at the Pivot Park in Oss, the Netherlands
New equipment at Exemplify
New 100 L vessels in Groningen
Organix: New facility
Innovative macrocycles as powerful Mcl-1 inhibitors
Oncolines unveils new state-of-the-art laboratories
Peter Molenveld assumes role as secretary of KNCV (Royal Netherlands Chemical Society)
Chiral chemistry: in the DNA of Symeres
π-facial selectivity in the Diels–Alder reaction of glucosamine-based chiral furans and maleimides
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities
Symeres acquires Exemplify BioPharma, further strengthening its strategic foothold in the US
Expansion of solid-state center of excellence
Symeres acquires Massachusetts-based Organix Inc., adding lipids expertise and creating a strategic foothold in the US market
Expanding the toolbox: Resolving racemates
Symeres joins forces with Keensight Capital
Speak with our experts
Let’s discuss how Symeres can support the discovery and development of your next breakthrough